< Back to latest news & events

Event

HGF webinar: Getting your first filing right

March 2022

Event date: 23rd March 2022

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right.

One of the most often asked questions of patent attorneys is: “when should we file?” Both timing and content of a first filing should be important strategic decisions. This is especially so in the therapeutic field where wide breadth of claim is desired coupled with maximum use of the available 21 year patent term from first filing. Circumstances can nevertheless necessitate a first filing needing to be considered in a pressurised situation. Even so, strategy from the start needs to be a matter of careful consideration to avoid later problems. The CRISPR patent battle in Europe illustrates well how first filing issues can be a source of costly, unwanted problems which are avoidable.

This presentation covered the considerations required at the first filing stage to align patenting strategy with commercial strategy and minimise problems arising from both formal and content issues. The presentation covered such issues as the evidence required to get over the plausibility hurdle in relation to inventive step and sufficiency as applied to compound and therapeutic use claims, as well as formal considerations such as where to file and who should file, often especially important considerations in the case of collaborative projects involving inventors outside the UK. The presentation also dealt with how to ensure you keep priority of a first filing both legally and to maximise disclosure benefit.

Speaker

Dr Claire Irvine – Partner & Patent Attorney

Watch the webinar:

Latest updates

The Antibody Series #2 Definition via binding strength in antibody claims: when “binds strongly... but only minimally...” becomes a trap of lack of clarity

Introduction Defining an antibody by its binding strength is common practice in patent claims, but it can quickly become a pitfall under Article 84 EPC on clarity. In this second …

Read article

The Antibody Series #1 Quality Characteristics (CQAs) in Antibody Claims: When the Test Method Can Remain Outside the Claim

Introduction Therapeutic antibodies are at the heart of innovations in biotechnology and healthcare. With increasing regulatory requirements and quality expectations, critical quality attributes (CQAs) are becoming essential in the drafting …

Read article
Event - 7th January 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Empowered, Not Replaced: The Risks and Rewards of Using AI Tools in Patent Prosecution

With the rapid rise of AI and extreme hype around generative AI tools in the workplace, patent firms around the world have had to seriously consider to what extent they …

Read article

EU Agrees on NGT Plant Regulation: What It Means for Patents and Licensing

The European Parliament and Council have reached a provisional agreement for plants developed using New Genomic Techniques (NGTs) – below we summarise the main points and set out the requirements …

Read article

When Retail Branding Meets Politics

(Inter IKEA Systems v Algemeen Vlaams Belang (Case C‑298/23) In November 2022, the Flemish political party Vlaams Belang presented its “IKEA-PLAN – Immigratie Kan Echt Anders” (“Immigration Really Can Be Different”). …

Read article

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article

Often Copied, Never Equaled: When Do Everyday Items Become Subject of Copyright?

The  borderline between ‘pure’ works of art and mere utilitarian objects” –  Can iconic, yet everyday products be protected under copyright? The above question was posed by Advocate General in …

Read article